Precigen
Open
$4.11
Prev. Close
$4.11
High
$4.12
Low
$4.11
Market Snapshot
$1.46B
-3.4
-0.48
$3.93M
160
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
emptyResult
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Recently from Cashu

Precigen Expects Over $18 Million in First-Quarter Sales for PAPZIMEOS Following J-Code Approval
In early April 2026, Precigen Inc. announces its expectations for first-quarter sales of its respiratory therapy, PAPZIMEOS, projected to exceed US$18 million. This optimistic forecast comes on the he…
Precigen Develops PAPZIMEOS™ for Treating Respiratory Papillomatosis and Advances in Immunology
Precigen Advances in Immunology: New Strategies for Treating Respiratory Papillomatosis In a notable development for the biopharmaceutical landscape, Precigen, Inc. reveals its focus on addressing sub…
Precigen Advances Regulatory Approvals and Expands Cancer Therapy Pipeline Despite Financial Losses
Precigen Advances Regulatory Approvals in Cancer Therapies Precigen, Inc., a biopharmaceutical company focused on innovative therapeutic solutions, is making notable strides in the fight against cance…
Precigen's PAPZIMEOS: First FDA-Approved Treatment for Recurrent Respiratory Papillomatosis
Precigen Achieves Milestone with FDA Approval of PAPZIMEOS Precigen, Inc. makes significant strides in the biopharmaceutical sector with the FDA’s approval of PAPZIMEOS (zopapogene imadenovec-drba), m…